---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-107277"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:47:37.863002+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology Q2 net loss $25.9M; cash runway into Q1 2027; CD47 biomarker data highlights evorpacept potential

## Summary
- GAAP net loss of $25.9M ($0.49/share) vs $39.4M ($0.76) in Q2 2024; R&D expense down 48% to $18.0M.
- Cash, equivalents & investments $83.5M; runway extended into Q1 2027 after pausing ASPEN-CRC trial.
- ASPEN-06 analysis: CD47-high HER2+ gastric cancer patients had 65% ORR with evorpacept + TRP vs 26% TRP alone; full data Q4 2025.
- ASPEN-Breast amended to single-arm biomarker-driven study; interim data expected Q3 2026.
- ALX2004 Phase 1 first patient dosing in August 2025; initial safety data 1H2026. Allison Dillon appointed COO; Daniel Curran appointed to Board.

## SEC filing metadata
- accession: 0000950170-25-107277
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017025107277/0000950170-25-107277-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017025107277/alxo-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-107277
- JSON: https://secwatch.observer/filing/0000950170-25-107277.json
- Plain text: https://secwatch.observer/filing/0000950170-25-107277.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.